Head to Head Contrast: CG Oncology (NASDAQ:CGON) and Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ:MYGN) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Earnings & Valuation

This table compares Myriad Genetics and CG Oncology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50 million	0.49	-$365.90 million	($1.19)	-3.53
CG Oncology	$4.04 million	1,387.04	-$160.99 million	($2.69)	-23.50

CG Oncology has lower revenue, but higher earnings than Myriad Genetics. CG Oncology is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Myriad Genetics and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Institutional and Insider Ownership

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Myriad Genetics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Myriad Genetics and CG Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3	4	1	0	1.75
CG Oncology	1	1	8	0	2.70

Myriad Genetics currently has a consensus target price of $3.93, indicating a potential downside of 6.37%. CG Oncology has a consensus target price of $87.50, indicating a potential upside of 38.41%. Given CG Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Myriad Genetics.

Summary

Myriad Genetics beats CG Oncology on 8 of the 14 factors compared between the two stocks.

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.